1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (401) 456-2398
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model
Article first published online: 26 JAN 2004
DOI: 10.1002/cncr.20060
Copyright © 2004 American Cancer Society
Additional Information
How to Cite
Ren-Heidenreich, L., Davol, P. A., Kouttab, N. M., Elfenbein, G. J. and Lum, L. G. (2004), Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model. Cancer, 100: 1095–1103. doi: 10.1002/cncr.20060
- †
Fax: (401) 456-2398
Publication History
- Issue published online: 18 FEB 2004
- Article first published online: 26 JAN 2004
- Manuscript Accepted: 11 DEC 2003
- Manuscript Revised: 18 NOV 2003
- Manuscript Received: 1 AUG 2003
Funded by
- Adele R. Decof Cancer Center
- Roger Williams Hospital
- Rhode Island Foundation. Grant Number: 20020742
- National Institutes of Health. Grant Number: R01 CA92344
- Department of Defense. Grant Number: BC996442
REFERENCES
- 1, , , . The biology of the 17-1A antigen (Ep-CAM). J Molec Med. 1999; 77: 699–712.
- 2, , , , . How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol. 1998; 10: 581–587.
- 3, , , , . Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Anticancer Res. 2000; 20: 1551–1555.
- 4, , . Introduction: bispecific antibodies. J Immunol Methods. 2001; 248: 1–6.
- 5, . Current perspectives of bispecific antibody-based immunotherapy. J Biol Regul Homeost Agents. 2000; 14: 175–181.
- 6, , , , , . A Phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer. Br J Cancer. 2001; 85: 152–156.
- 7, . Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy. Crit Rev Oncol Hematol. 2001; 38: 47–61.
- 8, , , . Bi-specific antibody therapy for the treatment of cancer. Curr Opin Mol Ther. 2001; 3: 53–62.
- 9, , . Immunotherapeutic perspective for bispecific antibodies. Immunol Today. 2000; 21: 391–397.
- 10, , , . Bi-specific antibodies in cancer therapy. Adv Exp Med Biol. 2000; 465: 369–80.
- 11. Bispecific antibodies in cancer therapy. Cancer J Sci Am. 2000; 6(Suppl 3): S265–S271.
- 12, , , , . The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res. 2000; 60: 1921–1926.
- 13, . Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988; 48: 7022–7032.
- 14. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990; 50: 814s–819s.
- 15, , , . Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Curr Pharm Des. 2000; 6: 261–276.
- 16, , , , , . Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods. 2001; 248: 47–66.
- 17, , , , , . Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol Immunother. 1997; 45: 193–197.
- 18, , , . Of mice and men: hybridoma and recombinant antibodies. Immunol Today. 2000; 21: 364–370.
- 19, , , , . Single-chain antibodies in pancreatic cancer. Ann NY Acad Sci. 1999; 880: 263–280.
- 20, , , et al. Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activation in vitro. Eur J Immunol. 2001; 31: 94–106.
- 21, , . Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors. Hum Gene Ther. 2000; 11: 9–19.
- 22, , , , , . In vivo selection of a highly metastatic cell line from a human pancreatic carcinoma in the nude mouse. Cancer. 1992; 69: 2060–2063.
- 23, , . Growth factor toxin chimeras and their applications. In: McKayIA BK, editor. Growth factors and receptors: a practical approach. Oxford: Oxford University Press, 1998: 199–225.
- 24, , . Bispecific antibodies in cancer therapy. Curr Opin Immunol. 1999; 11: 558–562.
- 25, , , . CO 17-1A and related monoclonal antibodies: their production and characterization. Hybridoma. 1986; 5(Suppl 1): S3–S10.
- 26, , , et al. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. Cancer Gene Ther. 2000; 7: 284–291.
- 27, , , , . Bispecific and bifunctional single chain recombinant antibodies. Biomol Eng. 2001; 18: 31–40.
- 28, , , et al. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model. J Immunol. 1998; 161: 1454–1461.
- 29, , , et al. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells. J Immunol. 2000; 165: 888–895.
- 30, , , et al. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody. Cancer Lett. 2002; 177: 29–39.
- 31, , , et al. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma. Cancer Immunol Immunother. 2002; 51: 33–44.